Skyline Therapeutics clinical trials
Acquired by Xiamen Amoytop Biotech Co., Ltd., Jul 29, 2025 · source ↗
The registry lists 2 studies whose lead sponsor is Skyline Therapeutics. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 1, 2026.
Before and after it joined Xiamen Amoytop Biotech Co., Ltd.
- First submitted before Skyline Therapeutics became part of Xiamen Amoytop Biotech Co., Ltd.
- 2
- First submitted after Skyline Therapeutics became part of Xiamen Amoytop Biotech Co., Ltd.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Skyline Therapeutics1 study
- Skyline Therapeutics (US) Inc.1 study
Something wrong with this grouping? Tell us on the Xiamen Amoytop Biotech Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All Xiamen Amoytop Biotech Co., Ltd. studies →
- A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMDRecruitingNCT06346600
Sponsor listed in the registry: Skyline Therapeutics · First submitted before Skyline Therapeutics became part of Xiamen Amoytop Biotech Co., Ltd.
- Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)RecruitingNCT05986864Phase 1/2
Sponsor listed in the registry: Skyline Therapeutics (US) Inc. · First submitted before Skyline Therapeutics (US) Inc. became part of Xiamen Amoytop Biotech Co., Ltd.